Sturchio A, Rocha E, Kauffman M, Marsili L, Mahajan A, Saraf A
Brain Sci. 2024; 14(2).
PMID: 38391726
PMC: 10887152.
DOI: 10.3390/brainsci14020151.
Chhabra P, Rishabh , Singla S, Choudhary S, Kohli S, Bansal N
CNS Neurol Disord Drug Targets. 2023; 23(8):996-1014.
PMID: 37815179
DOI: 10.2174/0118715273258646230920074421.
Gubinelli F, Sarauskyte L, Venuti C, Kulacz I, Cazzolla G, Negrini M
Curr Res Neurobiol. 2023; 4:100065.
PMID: 36632447
PMC: 9827042.
DOI: 10.1016/j.crneur.2022.100065.
Negrini M, Tomasello G, Davidsson M, Fenyi A, Adant C, Hauser S
J Parkinsons Dis. 2022; 12(4):1133-1153.
PMID: 35213388
PMC: 9198765.
DOI: 10.3233/JPD-212555.
Huntington T, Srinivasan R
Aging Dis. 2021; 12(4):1120-1137.
PMID: 34221553
PMC: 8219504.
DOI: 10.14336/AD.2021.0517.
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.
Cole T, Zhao H, Collier T, Sandoval I, Sortwell C, Steece-Collier K
JCI Insight. 2021; 6(5).
PMID: 33682798
PMC: 8021121.
DOI: 10.1172/jci.insight.135633.
Reverse engineering Lewy bodies: how far have we come and how far can we go?.
Fares M, Jagannath S, Lashuel H
Nat Rev Neurosci. 2021; 22(2):111-131.
PMID: 33432241
DOI: 10.1038/s41583-020-00416-6.
The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.
MacDougall G, Brown L, Kantor B, Chiba-Falek O
Mol Ther. 2021; 29(3):949-972.
PMID: 33429080
PMC: 7934639.
DOI: 10.1016/j.ymthe.2021.01.001.
On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson's and Huntington's Disease.
Troncoso-Escudero P, Sepulveda D, Perez-Arancibia R, Parra A, Arcos J, Grunenwald F
Front Aging Neurosci. 2020; 12:571185.
PMID: 33101007
PMC: 7497570.
DOI: 10.3389/fnagi.2020.571185.
Translation Imaging in Parkinson's Disease: Focus on Neuroinflammation.
Belloli S, Morari M, Murtaj V, Valtorta S, Moresco R, Gilardi M
Front Aging Neurosci. 2020; 12:152.
PMID: 32581765
PMC: 7289967.
DOI: 10.3389/fnagi.2020.00152.
Impact of α-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized α-synuclein rat model of PD.
Hoban D, Shrigley S, Mattsson B, Breger L, Jarl U, Cardoso T
Proc Natl Acad Sci U S A. 2020; 117(26):15209-15220.
PMID: 32541058
PMC: 7334514.
DOI: 10.1073/pnas.2001305117.
Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson J, Duffy M, Kemp C, Howe J, Collier T, Stoll A
Neurobiol Dis. 2019; 130:104525.
PMID: 31276792
PMC: 6701176.
DOI: 10.1016/j.nbd.2019.104525.
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved.
Vasili E, Dominguez-Meijide A, Outeiro T
Front Mol Neurosci. 2019; 12:107.
PMID: 31105524
PMC: 6494944.
DOI: 10.3389/fnmol.2019.00107.
Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K, Voutilainen M, Domanskyi A, Piepponen T, Ahola S, Tuominen R
J Neurosci Res. 2018; 97(3):346-361.
PMID: 30548446
PMC: 11863348.
DOI: 10.1002/jnr.24363.
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease.
Duffy M, Collier T, Patterson J, Kemp C, Fischer D, Stoll A
Front Neurosci. 2018; 12:621.
PMID: 30233303
PMC: 6132025.
DOI: 10.3389/fnins.2018.00621.
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson's disease.
Milanese C, Cerri S, Ulusoy A, Gornati S, Plat A, Gabriels S
Cell Death Dis. 2018; 9(8):818.
PMID: 30050065
PMC: 6062587.
DOI: 10.1038/s41419-018-0848-7.
Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.
Rodriguez-Perez A, Sucunza D, Pedrosa M, Garrido-Gil P, Kulisevsky J, Lanciego J
Neurotherapeutics. 2018; 15(4):1063-1081.
PMID: 29987762
PMC: 6277291.
DOI: 10.1007/s13311-018-0646-z.
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.
Zeng X, Geng W, Jia J, Chen L, Zhang P
Front Aging Neurosci. 2018; 10:109.
PMID: 29719505
PMC: 5913322.
DOI: 10.3389/fnagi.2018.00109.
Tis21-gene therapy inhibits medulloblastoma growth in a murine allograft model.
Presutti D, Ceccarelli M, Micheli L, Papoff G, Santini S, Samperna S
PLoS One. 2018; 13(3):e0194206.
PMID: 29538458
PMC: 5851620.
DOI: 10.1371/journal.pone.0194206.
New Developments in Genetic rat models of Parkinson's Disease.
Creed R, Goldberg M
Mov Disord. 2018; 33(5):717-729.
PMID: 29418019
PMC: 5992003.
DOI: 10.1002/mds.27296.